CG Oncology Rips 23.7% to $92 on PIVOT-006’s 68% Recurrence Cut; $112 Upside Target in Play
A 0.32 hazard ratio lifts CGON to $92; holding $80.97 opens $102 and $112 | That’s TradingNEWS
Key Points
- PIVOT-006 cut recurrence risk 68% versus surveillance, hazard ratio 0.32, p<0.0001
- CGON rose 23.7% premarket to $92, clearing its prior 52-week high of $80.97
- First BLA now due by end of March 2027, second BLA for intermediate-risk in Q2 2027
CG Oncology (NASDAQ: CGON) is trading at $92 in pre-market action on Monday, November 16, up 23.7%. The move follows topline results from the company’s Phase 3 PIVOT-006 registrational trial. Given after surgery, cretostimogene grenadenorepvec cut the risk of recurrence by 68% against surveillance in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The hazard ratio was 0.32, with a 95% confidence interval of 0.23 to 0.45 and a p-value below 0.0001. The stock has gone straight through its prior 52-week high of $80.97 and into price discovery.
The gap lands on top of a run that was already underway. CGON closed at $64.80 on November 5, the day before third-quarter results. On November 6 it jumped 20.27% intraday to $77.94 after beating earnings estimates and confirming a November date for the PIVOT-006 readout. It closed Thursday, November 12 at $70.15, then rose 5.9% on Friday into the $74 area as investors positioned for the data. From the November 5 close to Monday’s $92 indication, the stock is up 42% in seven sessions.
The broader tape is working against biotech this morning, which makes the move more striking. Before the open, Nasdaq 100 futures were down 0.97%, Nvidia was down 3.65% and the VIX sat above 20. CGON is ripping on a stock-specific catalyst in a risk-off market, a measure of how big the clinical surprise was.
The thesis is simple. PIVOT-006 has de-risked cretostimogene’s second and larger indication, with an effect size far beyond what the market expected. The pre-readout bar for a positive result was a 30% to 40% cut in recurrence risk, and the trial delivered 68%. It also showed no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations. Together, those results move cretostimogene from a single-indication story in BCG-unresponsive disease toward a potential backbone therapy across bladder-sparing NMIBC treatment.
The risks haven’t disappeared. The first Biologics License Application (BLA), for BCG-unresponsive disease, has slipped from fourth-quarter 2026 completion to before the end of March 2027 because the company is broadening the label. The second BLA, for intermediate-risk disease, is due in the second quarter of 2027. Neither has a PDUFA date yet. CG Oncology is still a single-asset company with $1.6 million of quarterly revenue and a $56.9 million quarterly net loss.
The forecast starts from the new floor. The prior $80.97 high is now the key support. Holding above it through the December 2 Society of Urologic Oncology presentation sets up a run to $102 and then the $112 upside target, the top of the analyst range. A fade back below $80.97 would mark the gap as a sell-the-news event and put the $74 pre-data level back in play.
PIVOT-006 Data: Hazard Ratio 0.32, 367 Patients, 17 Months of Follow-Up
The PIVOT-006 numbers are why the stock is repricing. The trial enrolled 367 patients at 90 sites in the United States and Canada and randomized them 1:1. Every patient first had the tumor fully removed by transurethral resection of bladder tumor (TURBT). One arm then received cretostimogene instilled into the bladder, and the other arm received surveillance, the current standard of care. The population covered intermediate-risk NMIBC and high-grade Ta tumors of 3 centimeters or less.
The primary endpoint was recurrence-free survival, and the trial met it with a hazard ratio of 0.32. In plain terms, patients on cretostimogene had a 68% lower risk of their cancer coming back during follow-up than patients under surveillance. The confidence interval ran from 0.23 to 0.45, so even the least favorable end of the range implies a 55% reduction in recurrence risk. The p-value was below 0.0001.
Median follow-up was 17 months at the October 26, 2026 data cutoff. That covers the recurrence window that matters most in intermediate-risk disease, where tumors often return within one to two years of resection. Longer follow-up is needed to confirm durability, but 17 months gives a credible read on the treatment effect.
The benefit held across disease grades. The company reported significant improvement in recurrence-free survival in both high-grade and low-grade patients but did not release separate hazard ratios for each group. Those subgroup figures, the Kaplan-Meier curves and recurrence-free survival rates at specific time points are expected on December 2, when PIVOT-006 gets a late-breaking podium presentation at the Society of Urologic Oncology (SUO) Annual Meeting.
The trial design matters to regulators. PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. A randomized comparison against surveillance carries far more weight with the FDA than a single-arm study, the design behind several recent bladder cancer approvals.
The enrollment pace was a signal in itself. CG Oncology finished enrollment 10 months ahead of schedule in September 2025, which the company attributed to strong patient and physician interest and the lack of approved options. That pace pulled the topline timeline forward, although the readout ultimately came in November rather than in the first-half 2026 window the company set in January.
For investors, the key number is the 0.32 hazard ratio, and the key detail still to come is how the recurrence curves separate over time. If the December presentation shows curves that keep widening through 17 months, the market will start pricing cretostimogene as a durable post-surgery standard rather than a short-term delay in recurrence.
Clearing the Bar: Why 68% Against a 30%–40% Benchmark Reprices the Stock
Expectations set the size of the move. Before the readout, the market’s bar for a positive PIVOT-006 result was a 30% to 40% cut in recurrence risk. Pre-readout models built around a 40% cut projected 20% upside for the shares. The trial came in at 68%, beating the top of that range by 28 percentage points.
That gap explains why the stock is up 23.7% rather than the 10% to 15% a merely positive result would have produced. Biotech stocks heading into binary Phase 3 readouts usually price a probability-weighted outcome, and estimates of the chance of success ran near 55%. A positive result removes the failure scenario. A dramatically positive one also raises the expected commercial value of success, so CGON is getting both re-ratings at once.
The size of the effect matters commercially as well as statistically. Intermediate-risk NMIBC is a disease of repeated recurrences: the tumor is removed, it comes back, and the patient goes back for another procedure. Each recurrence means another surgery under anesthesia, more cystoscopies and more cost. A 68% cut in recurrence risk translates directly into fewer procedures, which gives urologists, patients and payers a concrete reason to adopt the therapy.
A modest benefit would have left room to debate whether post-surgery treatment justifies the cost and inconvenience compared with simple surveillance. A 68% risk reduction largely settles that debate. It also sets a high bar for any competitor entering this setting, which would need to match or beat a 0.32 hazard ratio in a randomized trial.
The result also supports management’s broader strategy. CG Oncology describes cretostimogene as a potential backbone therapy across bladder-sparing NMIBC treatment. Until today, the clinical case rested mostly on single-arm BOND-003 data in BCG-unresponsive disease. PIVOT-006 adds randomized Phase 3 evidence in an earlier-stage population, which strengthens the case that the drug works across disease settings.
Biotech readouts rarely beat expectations by this margin. Most positive Phase 3 trials land within or just above the expected range, and many draw sell-the-news reactions. A result this far above the bar tends to bring in new holders, including generalist funds that avoided the binary risk before the readout. That buying can sustain the re-rating beyond the first day, especially with the December 2 presentation putting more detail in front of physicians and investors.
The question now shifts from whether the drug works to how fast it can reach the market and how much of the opportunity it can capture.
Safety: Zero Grade 3+ Treatment-Related Events Across More Than 700 Patients
Safety is the second pillar of the PIVOT-006 result, and it may matter as much as efficacy for adoption. The trial reported no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations, a profile the company said matched earlier studies.
That consistency now covers a large dataset. More than 700 NMIBC patients have been treated across BOND-003, CORE-008 and PIVOT-006. BOND-003 Cohort C, the BCG-unresponsive study behind the first BLA, had a 0% rate of Grade 3 or higher treatment-related adverse events. BOND-003 Cohort P, in papillary-only disease, reported no serious or Grade 3 or higher treatment-related events. CORE-008 Cohort CX, which combined cretostimogene with gemcitabine, reported no Grade 3 or higher treatment-related events, serious adverse events or deaths.
Tolerability is critical for intermediate-risk patients. Their disease recurs often but rarely progresses to life-threatening muscle-invasive cancer, so physicians are reluctant to expose them to toxic treatments. BCG, the standard bladder-instilled therapy for higher-risk disease, causes bladder irritation and flu-like symptoms and, in rare cases, systemic infection. A therapy that cuts recurrence by 68% with no serious treatment-related toxicity removes the main reason a urologist would choose surveillance instead.
The way the drug is given adds to the practical case. A nurse or medical assistant delivers cretostimogene into the bladder through a catheter. Management contrasts that with TAR-200, Johnson & Johnson’s device-based therapy, which needs cystoscopic procedures for placement and removal. An in-office instillation that doesn’t need a physician-performed procedure fits easily into existing urology workflows.
Cretostimogene is an oncolytic immunotherapy, a virus engineered to replicate selectively in bladder cancer cells with alterations in the Rb-E2F pathway, which are common in NMIBC. It also expresses GM-CSF, which stimulates an immune response. That dual mechanism, killing tumor cells directly while activating the immune system, supports the idea that the drug can work both in BCG-unresponsive disease and after surgery.
The safety record also lowers regulatory risk. The FDA weighs risk against benefit closely when the disease isn’t immediately life-threatening. A clean profile across more than 700 patients, combined with a randomized efficacy benefit, gives the agency a straightforward case and lowers the chance of restrictive label warnings that slow uptake.
For the stock, the safety data supports a broad commercial opportunity. A drug that is both effective and well tolerated can be used earlier and more often, which expands its potential patient base well beyond the BCG-unresponsive population where the first approval is expected.
BOND-003 and the First BLA: 75.5% CR Rate, but the Filing Slips to March 2027
The first regulatory filing rests on BOND-003, a Phase 3 single-arm trial in high-risk BCG-unresponsive NMIBC. Cohort C, which covers patients with carcinoma in situ with or without papillary tumors, produced strong data. In the 110-patient efficacy population, the complete response rate at any time was 75.5%, with a 95% confidence interval of 66.3% to 83.2%. The complete response rate was 46.4% at 12 months (51 of 110 patients) and 41.8% at 24 months (46 of 110).
Durability stands out. The median duration of response was 27.9 months, and 90% of 12-month responders were still disease-free at 24 months. At 24 months, 96.4% of patients had not progressed to muscle-invasive bladder cancer and 81.2% had avoided cystectomy. For BCG-unresponsive patients, whose main alternative is often surgical removal of the bladder, avoiding cystectomy is the central goal. The Cohort C results were published in The Lancet Oncology.
Cretostimogene holds FDA Fast Track and Breakthrough Therapy designations for this indication. The company began a rolling BLA submission in November 2025 and, after alignment discussions with the FDA, had guided to completing it in the fourth quarter of 2026.
That timeline has now moved. In Monday’s release, the company said it is broadening the first BLA to add high-grade papillary-only disease to the carcinoma in situ population. It now expects to complete the submission before the end of March 2027. The broader label would cover the BOND-003 Cohort P population, where high-grade event-free survival was 95.7% at three months, 84.6% at six months and 80.4% at nine months in 54 patients.
The trade-off is clear. A broader label expands the BCG-unresponsive market, but it pushes the filing back by up to a quarter. The FDA’s review clock starts when the BLA is complete, so a later submission means a later approval. With priority review, a decision would come six to eight months after completion, which points to a potential first approval in the second half of 2027.
For now, the market is looking past the delay because PIVOT-006 has overshadowed it. Manufacturing for both filings is complete, which removes the chemistry, manufacturing and controls (CMC) work that had been the gating item for the first BLA. The company had earlier said the remaining CMC module was progressing as planned.
For the stock, the slippage is a moderate negative that the data more than offsets. It extends the wait for commercial revenue and keeps CG Oncology reliant on its cash through 2027. It also leaves a window for competitors in the BCG-unresponsive setting to keep building share. Investors will want confirmation at the December presentation that the expanded BLA remains on track for March 2027.
December Data: BOND-003 Cohort P and CORE-008 Cohort CX 12-Month Readouts
The catalyst calendar doesn’t end with PIVOT-006. CG Oncology expects 12-month data from two more cohorts in December 2026, and both feed directly into the label strategy.
BOND-003 Cohort P covers high-risk BCG-unresponsive patients with papillary-only disease, meaning no carcinoma in situ. This is the population the company is adding to the first BLA. The early data are strong: in 54 patients, high-grade event-free survival was 95.7% at three months, 84.6% at six months and 80.4% at nine months, with no serious or Grade 3 or higher treatment-related adverse events. The 12-month readout will show whether that figure holds near 80% or starts to erode. A 12-month figure above 75% would support the broadened label and strengthen cretostimogene against other BCG-unresponsive therapies.
CORE-008 Cohort CX tests cretostimogene with gemcitabine in high-risk patients who are BCG-exposed or BCG-unresponsive. Arm 1 gives the two drugs together and Arm 2 gives them in sequence. In the 55-patient intent-to-treat population (28 in Arm 1, 27 in Arm 2), high-grade event-free survival was 96.0% at three months and 89.5% at six months, with median follow-up of 6.6 months. Among patients evaluable for efficacy, the complete response rate at any time was 71.4% (20 of 28) in the concurrent arm and 100% (27 of 27) in the sequential arm. The cohort reported no Grade 3 or higher treatment-related adverse events, serious adverse events or deaths.
The 100% complete response rate in the sequential arm is a striking early figure, though the sample is small. If the 12-month data show durable responses there, the combination could open earlier high-risk settings and help defend against competitors building their own combination regimens.
These December readouts carry less binary risk than PIVOT-006, but they shape the size of the long-term opportunity. Durable Cohort P data supports the first BLA, and strong CORE-008 data supports future label expansion. Together with PIVOT-006, they build the case for using cretostimogene across bladder-sparing NMIBC treatment, from post-surgery therapy in intermediate-risk disease to BCG-unresponsive disease.
The timing works in the stock’s favor. With the SUO presentation on December 2 and the 12-month data later in December, CGON has a run of catalysts through year-end that lean positive. Each one gives new investors a reason to build positions and existing holders a reason not to sell into the gap.
The Market Opportunity: 50,000 Intermediate-Risk Patients and a Path to 150,000+
PIVOT-006 opens the larger of cretostimogene’s markets. The company estimates 50,000 U.S. patients with intermediate-risk NMIBC, based on National Cancer Institute SEER claims data and management assumptions. No FDA-approved treatment exists for these patients after tumor removal. Today they are monitored with surveillance cystoscopies and go back to surgery when tumors recur.
That 50,000-patient segment is part of a larger target. The company outlines a path to more than 150,000 addressable U.S. patients across NMIBC segments of 50,000, 50,000, 25,000 and 25,000 patients. Bladder cancer is one of the most common U.S. cancers, with more than 85,000 new cases a year and more than 730,000 people living with the disease. Most cases are non-muscle invasive at diagnosis, and the high recurrence rate makes it one of the most expensive cancers to treat over a patient’s lifetime.
The intermediate-risk market has specific advantages. Patients cycle through multiple recurrences over many years, so a therapy that prevents recurrences gets used repeatedly across a large population. The 68% risk reduction gives payers a clear economic argument, because each avoided recurrence saves a TURBT procedure, anesthesia and follow-up imaging. Urologists already perform bladder instillations in the office, so adoption doesn’t need new infrastructure.
Commercial preparation is underway. In October, CG Oncology named Isabel Kalofonos Chief Commercial Officer. She brings more than 20 years of launch experience, including PALSONIFY and ELAHERE. The company has also opened an Expanded Access Program in North America for eligible BCG-unresponsive patients, which builds physician familiarity with the drug before approval.
The company already books small amounts of commercial and development revenue: $1.604 million in the third quarter and $3.820 million over the first nine months of 2026. The line is minor today, but it shows the structures for booking product sales are in place.
The size of the opportunity is what justifies the valuation after Monday’s gap. Even modest penetration of a 150,000-patient market with a premium-priced immunotherapy implies multibillion-dollar revenue at maturity. In intermediate-risk disease alone, with no approved competitor and a randomized Phase 3 result, cretostimogene has a first-mover position that could hold for several years.
Competitive Landscape: Inlexzo, Anktiva, Adstiladrin, Keytruda and UroGen
The BCG-unresponsive setting, where cretostimogene’s first approval is expected, has grown crowded. Johnson & Johnson’s gemcitabine-releasing system Inlexzo, developed as TAR-200, won FDA approval in September 2025. ImmunityBio’s Anktiva, Ferring’s Adstiladrin and Merck’s Keytruda are also approved for BCG-unresponsive disease, each with a different mechanism and way of being given.
Cretostimogene’s BOND-003 data compare well with that field. A 75.5% complete response rate at any time and 41.8% at 24 months, with no Grade 3 or higher treatment-related events, make one of the strongest combinations of efficacy, durability and tolerability in the class. Management argues its delivery advantage over Inlexzo matters in practice. A nurse or medical assistant instills cretostimogene through a catheter, while TAR-200 needs cystoscopic placement and removal.
The intermediate-risk setting is less crowded. UroGen’s mitomycin formulation, instilled into the bladder, is FDA-approved for recurrent low-grade intermediate-risk disease, but the approval was controversial. It rested on a single-arm trial, ENVISION, and an FDA advisory committee voted 4 to 5 against approval. UroGen’s product is a chemoablation treatment that destroys existing tumors rather than a therapy given after surgery, so it targets a different point in the treatment pathway.
PIVOT-006 gives cretostimogene a clear advantage here. It is the first randomized Phase 3 registrational trial in intermediate-risk and high-grade Ta NMIBC, and it compared the drug directly with surveillance, the current standard. No other agent has randomized evidence in this post-surgery population. That positions cretostimogene to become the first FDA-approved therapy for these patients after tumor removal, with a dataset competitors will struggle to match.
Competition will still shape pricing and uptake. Large drugmakers with established urology sales forces, including Johnson & Johnson and Merck, can bundle products and outspend a newly commercial company. CG Oncology will launch one product with a new commercial organization. Success will depend on how fast it builds relationships with urology practices, secures reimbursement and stands out on outcomes.
The competitive picture also raises a strategic question. A single-asset company with a best-in-class profile across several NMIBC settings is a natural acquisition target for larger oncology players looking to expand in bladder cancer, and Monday’s data raise that strategic value. The company is well funded and focused on selling the drug itself, but takeover speculation tends to support biotech valuations after decisive Phase 3 wins.
Q3 Financials: $56.9 Million Net Loss, $984.5 Million Cash, Runway Through 2029
CG Oncology’s finances give it time to execute. It reported a third-quarter net loss of $56.9 million, or $0.64 per share, against a consensus estimate of $0.83 per share. Revenue of $1.604 million beat the $548,000 estimate. Results came out on November 6.
Spending is rising as the company prepares two filings and a launch. Research and development expenses reached $39.2 million in the third quarter, up 41% from $27.9 million a year earlier. Clinical trial costs, including CMC work, and a larger headcount drove the increase. General and administrative expenses were flat at $23.0 million against $23.3 million a year earlier, as lower professional fees offset higher personnel costs. Cost of sales rose to $2.669 million from $1.577 million.
The quarter’s operating loss was $63.2 million, partly offset by $6.4 million of net interest income. Over the first nine months of 2026, R&D spending rose 59% to $137.6 million and the net loss widened 64% to $196.1 million, or $2.25 per share. Nine-month general and administrative costs reached $72.7 million against $55.5 million a year earlier.
The balance sheet is strong. Cash, cash equivalents and marketable securities totaled $984.5 million at September 30, up from $742.2 million at the end of 2025 after equity raises earlier in the year. The company held $1.0 billion at June 30, so third-quarter cash burn matched the operating loss. Total liabilities were just $55.7 million against stockholders’ equity of $991.0 million.
Management expects current resources to fund operations through 2029. At a quarterly operating loss near $63 million, the cash covers more than 15 quarters of spending. That carries the company through both BLA filings, potential approvals in 2027 and the early years of a launch without new capital.
That matters after Monday’s gap. Biotechs often sell new shares right after positive Phase 3 data to take advantage of the higher price, and CG Oncology doesn’t need to. If it raises anyway to speed the launch, it can do so from strength at a price above $90, which limits dilution. Weighted average shares rose to 88.9 million in the third quarter from 76.7 million a year earlier because of past raises, so investors will watch for any new offering.
That removes one of the biggest risks for a single-asset biotech, the need to raise money at a bad time. With $984.5 million of cash and a runway through 2029, CG Oncology can focus on execution.
Valuation: Market Value Above $8 Billion and Analyst Targets From $80 to $112
At $92, CG Oncology has a market value above $8 billion. Net of $984.5 million in cash and marketable securities, its enterprise value is above $7 billion. That is what the market now assigns to cretostimogene’s future revenue across BCG-unresponsive and intermediate-risk NMIBC.
Analyst targets set the reference range. Before Monday’s data, 13 analysts had an average 12-month price target of $92.15, with individual targets from $80 to $112. Of 15 covering analysts, 14 rated the stock a Buy, one a Hold and none a Sell. One target was raised to $102 from $93 on November 13, ahead of the readout. Others sat at $100, $89, $85, $84 and $79.
Monday’s $92 pre-market price lands almost exactly on that pre-data average. In other words, the stock has already moved to where analysts expected it to trade after a successful readout. The question now is how far analysts lift their targets after a result that beat their own bar by a wide margin. Most models assumed a 30% to 40% risk reduction and an approval probability near 55%. Updated models will carry a higher chance of approval in intermediate-risk disease and higher peak sales to reflect the 68% effect.
A realistic re-rating would push the average target toward the top of the current range. The $112 high target, 21.7% above Monday’s indication, is the logical upside target. Revised targets above $112 over the next two weeks would confirm the stock still has room to run. If targets cluster at $95 to $100 instead, the stock may already be pricing most of the good news.
The cash balance gives the valuation a cushion: at $92, cash covers 12% of the market value. That won’t stop a decline if sentiment turns, but it limits the downside compared with a biotech that needs capital.
The broader opportunity frames the upside. An enterprise value above $7 billion against more than 150,000 addressable U.S. patients works out to less than $50,000 per patient. For a premium-priced immunotherapy with no approved competitor after surgery and a best-in-class profile in BCG-unresponsive disease, that leaves room to expand if the launch goes well. It also leaves the stock exposed if approvals slip further or uptake disappoints.
Risks: Single Asset, BLA Timing, ANI Royalty Litigation and a Risk-Off Tape
PIVOT-006 removes the largest clinical risk, but several others remain. The first is concentration. CG Oncology depends entirely on cretostimogene, so any regulatory setback, manufacturing problem or post-approval safety signal would hit the whole company rather than one product in a portfolio.
The second is regulatory timing. The first BLA has slipped from fourth-quarter 2026 completion to before the end of March 2027, and the second isn’t due until the second quarter of 2027. Neither filing has a PDUFA date. FDA review timelines can shift, and agency resources have been stretched in recent years. A potential first approval in the second half of 2027 means no meaningful product revenue for at least a year, while competitors keep building share in BCG-unresponsive disease.
The third is the pending litigation with ANI Pharmaceuticals over a claimed 5% royalty. The outcome of the appeal is uncertain. A ruling against CG Oncology would create a liability that cuts future margins on cretostimogene sales. The exposure isn’t quantified, but a 5% royalty on a multibillion-dollar product would be material.
The fourth is manufacturing and supply. Manufacturing for both filings is complete, which lowers near-term CMC risk, but CG Oncology relies on third parties for manufacturing, shipping and testing. Oncolytic viral therapies are complex biologics, and scaling production for a large commercial launch carries execution risk.
The fifth is the market backdrop. Monday’s tape is risk-off, with Nasdaq 100 futures down 0.97%, Nvidia down 3.65% before the open and the 10-year Treasury yield at 5.15%. Rising rates hit growth stocks whose cash flows are far in the future, and biotechs are among the most sensitive. A broader selloff could pull CGON lower even as its fundamentals improve. The stock’s beta of 0.35 offers some insulation, but big single-day gaps often attract profit-taking when the overall market weakens.
The sixth is the gap itself. A 23.7% pre-market move hands many earlier holders large gains. Funds that bought the binary bet ahead of the readout may sell into strength to lock in profits. If the stock fails to hold its opening level, the reversal could be sharp. The prior $80.97 high separates a constructive consolidation from a failed breakout.
None of these risks undermines the clinical case. They do argue for a measured view of how fast the stock can climb, and for watching the $80.97 support through the December catalysts.
Technical Map: $80.97 Support, $92 Pivot, $102 Resistance, $112 Target
The technical picture changed overnight. CGON’s 52-week range ran from $35.80 to $80.97 before Monday. The $92 pre-market indication puts the stock 13.6% above that prior high and 157% above the 52-week low, in territory with no prior resistance overhead.
The first support is the $80.97 prior high. In a classic breakout, old resistance becomes support. A pullback that holds above $80.97 on a closing basis would confirm the breakout and set a base for the next leg higher. The second support is November 6’s $77.94 intraday high, set on third-quarter results day. Below that, the $74 area, Friday’s pre-data level, marks the gap fill. A close back near $74 would show the market had fully faded the PIVOT-006 news.
The first resistance is the opening print itself. Large pre-market gaps often open with a spike and then sell off intraday as early buyers take profits, so where the stock closes will set the tone for the week. A close at or above $92 would show strong demand absorbing the supply. A close in the mid-$80s would still be constructive if it holds above $80.97.
The next resistance is $102, the target one analyst set on November 13. Above that, $112 is the top of the analyst range and the upside target for this forecast. From $92, $102 is a 10.9% gain and $112 is a 21.7% gain.
Volume will confirm the move. Friday’s 5.9% advance came on volume 29% below average, which showed pre-data positioning was cautious rather than crowded. Monday should bring several times normal volume. Sustained heavy volume with the price above $80.97 would point to institutional accumulation rather than a retail-driven spike.
The trading plan follows those levels. A daily close above $92 opens $102 heading into the December 2 presentation. A close above $102, backed by detailed recurrence curves, opens the $112 upside target. A pullback to $81 to $85 that holds the prior high is a buying zone for investors who missed the gap. A close below $80.97 would invalidate the breakout and put $77.94 and the $74 gap fill in play. From a $92 entry, a stop just below $80.97 risks $11.03 per share to make $20 to the $112 target, a 1.8-to-1 ratio. An entry near $85 on a pullback, with the same stop, risks $4.03 to make $27, close to 6-to-1.
Catalyst Calendar: SUO December 2, 12-Month Data in December, BLAs in Q1 and Q2 2027
CG Oncology’s catalyst calendar is dense through mid-2027, and most events now carry upside skew rather than binary risk.
The first is the late-breaking PIVOT-006 podium presentation at the SUO Annual Meeting on December 2, 2026. It will show the full recurrence-free survival curves, subgroup hazard ratios for high-grade and low-grade patients, recurrence rates at specific time points and detailed safety data. The key items are whether the curves keep separating through 17 months and whether the benefit holds evenly across subgroups. A strong presentation would push analysts to raise targets and draw more institutional buying.
The second is the December 2026 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX. Cohort P supports the broadened first BLA, and CORE-008 tests the combination with gemcitabine. Durable responses in both would strengthen the label and the long-term growth story.
The third is completion of the first BLA, for BCG-unresponsive NMIBC with carcinoma in situ and high-grade papillary-only disease, before the end of March 2027. Completion starts the FDA review clock. With Breakthrough Therapy designation, the company could get priority review, putting a potential approval decision in the second half of 2027.
Read More
-
Yen Stalls at 160 Despite a 3% JGB and Tokyo Core CPI at 2.0% — Intervention Sits at 164, Friday's Payrolls Decide
02.09.2026 · TradingNEWS ArchiveEnergy
-
QQQ Drops to $662.15 Below Its 200-Day Line as Chip Curbs Hit Nvidia; Reclaiming $682 Opens $700 Upside Target
16.11.2026 · TradingNEWS ArchiveStocks
-
Bitwise XRP ETF Hits $10.65 Low as XRP ETFs Bleed $19.13M; A Close Above $11.42 Opens the $12.80 Upside Target
16.11.2026 · TradingNEWS ArchiveCrypto
-
December Natural Gas Slips to $3.154 on Warmer Models; Record Shorts Keep a $3.40 Upside Target in Play
16.11.2026 · TradingNEWS ArchiveCommodities
-
USD/JPY Holds 159.55 Under Tokyo’s 160 Line; A Close Above 160.19 Opens the 160.50 Upside Target
16.11.2026 · TradingNEWS ArchiveForex
The fourth is the second BLA, for intermediate-risk and high-grade Ta NMIBC based on PIVOT-006, expected in the second quarter of 2027. It covers the larger market, where no approved competitor exists for use after surgery.
Beyond those, investors will watch for FDA acceptance letters and PDUFA dates once the filings are complete, any advisory committee scheduling, progress on the commercial build-out under the new Chief Commercial Officer, and updates on the ANI royalty appeal.
The broader market calendar matters this week too. Nvidia reports after Tuesday’s close, the FOMC minutes arrive Wednesday and Anthropic’s IPO starts trading Thursday. Those events will drive the risk mood across growth stocks and could affect whether CGON holds its gap in the first week.
That sequence gives CGON a steady stream of news over the next six months. Each event either confirms the PIVOT-006 result or moves the drug closer to approval.
Verdict: Bullish Above $80.97, Targeting $102 Then $112
At $92, CG Oncology is a different company from the one that closed at $64.80 on November 5. PIVOT-006 cut recurrence risk by 68%, with a 0.32 hazard ratio and a p-value below 0.0001, in the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. That beat the market’s 30% to 40% bar by a wide margin. The trial reported no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations, consistent with a safety record across more than 700 patients.
The opportunity is large. Intermediate-risk disease alone covers 50,000 U.S. patients with no FDA-approved treatment after surgery, and the company sees a path to more than 150,000 addressable patients. BOND-003 supports a first approval in BCG-unresponsive disease with a 75.5% complete response rate, and 41.8% at 24 months. The company holds $984.5 million of cash, enough to fund operations through 2029 without new capital.
The risks are real but manageable. The first BLA has slipped to before the end of March 2027, the second is due in the second quarter of 2027, and neither has a PDUFA date. The company relies on a single asset, faces royalty litigation and must build a commercial organization from scratch. The broader market is risk-off on Monday, and a 23.7% gap invites profit-taking.
The verdict is bullish above $80.97, the prior 52-week high that separates a valid breakout from a failed one. Holding it through the December 2 SUO presentation sets up a move to $102. Detailed data showing the recurrence curves keep separating would then open the $112 upside target, 21.7% above Monday’s indication. Analyst target revisions over the coming days will show how much of that upside the market is ready to price.
A close below $80.97 would weaken the setup and put $77.94 and the $74 gap fill in play. That would most likely come from a broad market selloff rather than any change in the clinical case. For investors who missed the gap, a pullback to $81 to $85 that holds the prior high is a better entry than chasing the opening print. For existing holders, the December catalysts argue for holding through the presentation, with $80.97 as the line for managing risk.